Catalyst Pharmaceuticals

Catalyst is developing amifampridine phosphate for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that amifampridine phosphate has the potential to treat other neuromuscular disorders such as congenital myasthenic syndromes and some cases of myasthenia gravis that are refractory to currently approved therapies.
Type
Public
HQ
Coral Gables, US
Founded
2002
Size (employees)
18 (est)-21%
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, US

Catalyst Pharmaceuticals Office Locations

Catalyst Pharmaceuticals has an office in Coral Gables
Coral Gables, US (HQ)
1250 355 Alhambra Cir

Catalyst Pharmaceuticals Data and Metrics

Catalyst Pharmaceuticals Financial Metrics

Catalyst Pharmaceuticals's revenue was reported to be $0 in FY, 2016
USD

Net income (FY, 2016)

(18.1 m)

EBIT (FY, 2016)

(19.3 m)

Market capitalization (23-Jun-2017)

238 m

Closing share price (23-Jun-2017)

2.8

Cash (31-Dec-2016)

13.9 m
Catalyst Pharmaceuticals's current market capitalization is $238 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

10.1 m11.8 m11.4 m

General and administrative expense

4.5 m8.6 m7.9 m

Operating expense total

14.6 m20.4 m19.3 m

EBIT

(14.6 m)(20.4 m)(19.3 m)

Pre tax profit

(15.5 m)(20.2 m)(18.1 m)

Net Income

(15.5 m)(20.2 m)(18.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.2 m9.1 m28.2 m13.9 m

Inventories

4.6 m1.5 m1 m

Current Assets

25.3 m43.8 m59.9 m41.5 m

PP&E

40.6 k71.4 k191.5 k244.2 k

Total Assets

25.4 m43.9 m60.1 m41.7 m

Accounts Payable

850.8 k1.8 m1.8 m933.2 k

Current Liabilities

2.1 m5.9 m3.4 m2.1 m

Additional Paid-in Capital

75.7 m105 m145.5 m147.4 m

Retained Earnings

(69.8 m)(90.1 m)(108.1 m)

Total Equity

21.4 m35.2 m55.5 m39.3 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.2 m)(15.5 m)(20.2 m)(18.1 m)

Depreciation and Amortization

22.5 k26.6 k34.5 k43.4 k

Accounts Payable

(514.9 k)963.4 k(20.1 k)(861 k)

Cash From Operating Activities

(9.9 m)(12.9 m)(18 m)(18 m)

Capital Expenditures

(9.4 k)(57.3 k)(23.5 k)(96.1 k)

Cash From Investing Activities

(7.5 m)(8.7 m)(6.5 k)3.6 m

Cash From Financing Activities

18.2 m28.6 m37.2 m69 k

Free Cash Flow

(9.9 m)(13 m)(18 m)(18.1 m)
Y, 2016

Financial Leverage

1.1 x

Catalyst Pharmaceuticals Market Value History

Catalyst Pharmaceuticals Online and Social Media Presence

Catalyst Pharmaceuticals Company Life and Culture

You may also be interested in